Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry DOI
Simona Di Martino, Pietro Amico, Maria De Rosa

et al.

Topics in Current Chemistry, Journal Year: 2025, Volume and Issue: 383(2)

Published: March 21, 2025

Language: Английский

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies DOI Open Access
Suman Adhikari, Priyatosh Nath, Alakesh Das

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 171, P. 116211 - 116211

Published: Jan. 29, 2024

Research into cancer therapeutics has uncovered various potential medications based on metal-containing scaffolds after the discovery and clinical applications of cisplatin as an anti-cancer agent. This resulted in many metallodrugs that can be put medical applications. These have a wider variety functions mechanisms action than pure organic molecules. Although platinum-based medicines are very efficient agents, they often accompanied by significant side effects toxicity limited resistance. Some most studied developed alternatives to include ruthenium, gold, copper, iridium, osmium, which showed effectiveness against cell lines. metal-based represent exciting new category treatments sparked renewed interest search for effective therapies. Despite widespread development metal complexes touted powerful promising vitro therapeutics, only small percentage these compounds shown their worth vivo models. Metallodrugs, more less toxic drugs treat drug-resistant cells, focus this review. Here, we highlighted some recently Pt, Ru, Au, Cu, Ir, Os antitumor properties between 2017 2023.

Language: Английский

Citations

68

Riding the metal wave: A review of the latest developments in metal-based anticancer agents DOI

Sara Abdolmaleki,

Alireza Aliabadi, Samad Khaksar

et al.

Coordination Chemistry Reviews, Journal Year: 2023, Volume and Issue: 501, P. 215579 - 215579

Published: Nov. 28, 2023

Language: Английский

Citations

63

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs DOI Creative Commons
Lozan Todorov, Irena Kostova

Molecules, Journal Year: 2023, Volume and Issue: 28(4), P. 1959 - 1959

Published: Feb. 18, 2023

Since the accidental discovery of anticancer properties cisplatin more than half a century ago, significant efforts by broad scientific community have been and are currently being invested into search for metal complexes with antitumor activity. Coordination compounds transition metals such as platinum (Pt), ruthenium (Ru) gold (Au) proven their effectiveness diagnostic and/or antiproliferative agents. In recent years, experimental work on potential applications elements including lanthanum (La) post-transition gallium (Ga) in field oncology has gaining traction. The authors present review article aim to help reader “catch up” some latest developments vast subject coordination oncology. Herewith is offered published literature Pt, Ru, Au, Ga La that released over past three years hope readers find following informative helpful.

Language: Английский

Citations

33

The Importance of Being Casiopeina as Polypharmacologycal Profile (Mixed Chelate–Copper (II) Complexes and Their In Vitro and In Vivo Activities) DOI Creative Commons
Zenayda Aguilar-Jiménez, Adrián Espinoza-Guillén, Karen Reséndiz-Acevedo

et al.

Inorganics, Journal Year: 2023, Volume and Issue: 11(10), P. 394 - 394

Published: Oct. 7, 2023

In this review, we present a timeline that shows the origin of mixed chelate copper (II) complexes, registered as Mark Title Casiopeínas®, first compounds proposed anticancer drugs in 1988 and 1992. late twentieth century, use essential metals agents was not even considered, except for their antifungal or antibacterial effects; also, copper, gold salts, used arthritis problems. The to diminish secondary toxic effects Cisplatin our driving force: find less more economical under rational design metal complexes. Due chemical properties, were choice continue drug development. order ideas, designs chelate–copper complexes (Casiopeínas, (Cas) homoleptic heteroleptic, depending on nature ligand) synthesized fully characterized. search new, effective, drugs, Casiopeína® emerged family approximately 100 from coordinated Cu(II) with proven antineoplastic potential through cytotoxic action. Cas have general formula [Cu(N–N)(N–O)]NO3 [Cu(N–N)(O–O)]NO3, where N–N is an aromatic substituted diimine (1,10-phenanthroline 2,2′-bipyridine), oxygen donor (O–O) acetylacetonate salicylaldehyde. Lately, some similar been developed by other research groups considering hypothesis after Casiopeína’s discoveries had published, described herein. As example translational medicine criteria, covered each step established normative process development, consequently, one molecules (Casiopeína III ia (CasIIIia)) has reached clinical phase I. For these compounds, activities, such antibacterial, antiparasitic antiviral, discovered.

Language: Английский

Citations

23

Visible and Red Light-Triggered Anticancer Profile of a Ferrocene-Re(I)-Tricarbonyl Conjugate: Experimental and Theoretical Studies DOI
Rajesh Kushwaha, Aarti Upadhyay, Silda Peters

et al.

Langmuir, Journal Year: 2024, Volume and Issue: 40(23), P. 12226 - 12238

Published: May 30, 2024

We have red-shifted the light absorbance property of a Re(I)-tricarbonyl complex via distant conjugation ferrocene moiety and developed novel ReFctp, [Re(Fctp)(CO)3Cl], where Fctp = 4′-ferrocenyl-2,2′:6′,2″-terpyridine. ReFctp showed green to red absorption ability blue emission, indicating its potential for photodynamic therapy (PDT) application. The introduced ferrocene-based transitions, which lie at higher wavelength within PDT therapeutic window. time-dependent density functional theory excited state calculations revealed an efficient intersystem crossing is helpful PDT. elicited both type I II pathways reactive oxygen species (ROS) generation facilitated NADH (1,4-dihydro-nicotinamide adenine dinucleotide) oxidation upon exposure visible light. Importantly, effective penetration through layers clinically relevant 3D multicellular tumor spheroids localized primarily in mitochondria (Pearson's correlation coefficient, PCC 0.65) A549 cancer cells. produced more than 20 times phototoxicity (IC50 ∼1.5 μM) by inducing ROS altering mitochondrial membrane cells nonferrocene analogue Retp, [Re(CO)3(tp)Cl], tp 2,2′:6′,2″-terpyridine. induced apoptotic mode cell death with notable photocytotoxicity index (PI, PI IC50dark/IC50light) selectivity (SI, SI normal cell's IC50dark/cancer IC50light) range 25–33.

Language: Английский

Citations

9

THE ROLE OF CONTINUOUS MONITORING IN ONCOLOGY PATIENTS RECEIVING RADIOTHERAPY OR CHEMOTHERAPY. REVIEW DOI Open Access

Davit Mathevosyan

BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY, Journal Year: 2025, Volume and Issue: unknown, P. 88 - 98

Published: Jan. 10, 2025

Background: Oral cancer is a major public health problem worldwide and the prevention of oral its associated morbidity mortality depends on early detection. Delayed diagnosis contributor to dismal survival rate over five years.Currently, various monitoring methods have been actively used for purpose active detection asymptomatic cancer. This study provides an overview main concepts principles organizing continuous in oncology patients receiving radiotherapy or chemotherapy. Methods: review was reported per PRISMA guidelines conducted publications covering scientific research diagnostics, management protocols, radiotherapy, chemotherapy malignant neoplasms Medline, Scopus, Web science, PubMed (search 162 which finally included 75 articles). Two authors screened results searches against inclusion criteria, extracted data assessed risk bias independently duplicate. Results: To prevent minimize complications, appropriate protocol needed should include assessment prior treatment. Early recognition can improve patient reduce morbidity. Conclusion: Continuous with primary care settings radiation therapy may complications effectiveness combination therapy. cavity, it very important pre-treat existing diseases, this aspect, cooperation dentist oncologist as one team important. will help dental practitioners manage risks potential requiring

Language: Английский

Citations

1

Bridging the gap between theory and treatment: Transition metal complexes as successful candidates in medicine DOI

Sara Abdolmaleki,

Alireza Aliabadi, Samad Khaksar

et al.

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 531, P. 216477 - 216477

Published: Feb. 8, 2025

Language: Английский

Citations

1

Pincer‐Type Pt(II)‐NHC Antibody‐Drug Conjugate for HER‐2‐Targeted Chemoimmunotherapy DOI Creative Commons
Tao Huang,

Wei-Ta Huang,

G. M. Huang

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Platinum-based chemotherapy drugs play an indispensable role in clinical cancer treatment, but exhibit considerable side effects due to their non-specific mechanism of killing cells and normal cells. In this regard, the use antibodies conjugated anti-cancer platinum complexes will enable better differentiation from Here, six pincer-platinum(II) NHC (N-heterocyclic carbene) are reported, one which has amino group on N-alkyl ligand. This platinum(II) complex is used as payload for platinum(II)-based antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER-2). Notably, ADC can specifically bind HER-2 antigen, distinguish target non-target cells, good anti-tumor activity vitro vivo.

Language: Английский

Citations

1

Exploring the Future of Metal‐Based Anticancer Agents: A Comprehensive Review of Ruthenium‐Based Complexes DOI Open Access
Syamal D. Bhattacharya, Tenzin Adon, Karen M. DSouza

et al.

ChemistrySelect, Journal Year: 2025, Volume and Issue: 10(9)

Published: March 1, 2025

Abstract Ruthenium complexes are gaining recognition in oncology as promising alternatives to the traditionally used platinum‐based anticancer agents. Unlike Pt agents, they can better differentiate between healthy and malignant cells, minimizing adverse side effects. They exhibit advantageous properties such thermodynamic kinetic stability, increased water solubility, enhanced cellular absorption, superior selectivity cytotoxicity for tumors, decreased toxicity cells. has been make having structural variability ability undergo ligand exchange. effective against metastatic tumor cells interact with components; their significant charges large cavities allow efficient molecule encapsulation. These being explored enhance efficacy enzymatic research targeted therapies. The manifold biochemical of ruthenium induce cell apoptosis through various signaling pathways them candidates future Despite successful testing some these clinical trials, none have commercially available. Continued aims unlock full potential cancer treatment. This review covers a few findings past 6 years on ligated organic moieties antineoplastic

Language: Английский

Citations

1

Research Progress of Metal Anticancer Drugs DOI Creative Commons
Yun Bai,

Gerile Aodeng,

Lu Ga

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(12), P. 2750 - 2750

Published: Dec. 11, 2023

Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent 50 cancer patients who able receive conventional chemotherapy survive. Because factors, being develop a treatment that can target cells without affecting normal remains big challenge. Since special properties cisplatin in malignant tumors were accidentally discovered last century, metal anticancer drugs become research hotspot. Metal unique pharmaceutical properties, such as ruthenium with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, so on. recent years, efficient low-toxicity antitumor complexes been synthesized. this paper, scientific literature on platinum (Pt), (Ru), iridium (Ir), gold (Au), other was reviewed referring large amount relevant at home abroad.

Language: Английский

Citations

23